Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies

The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid malignancies such as diffuse large B cell lymphoma (DLBCL) are frequently intrinsically resistant to venetoclax. Although genomic...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Stephen Jun Fei, Zhu, Fen, Dashevsky, Olga, Mizuno, Rin, Lai, Jolin X.H., Hackett, Liam, Ryan, Christine E., Collins, Mary C., Iorgulescu, J. Bryan, Guièze, Romain, Penailillo, Johany, Carrasco, Ruben, Hwang, Yeonjoo C., Muñoz, Denise P., Bouhaddou, Mehdi, Lim, Yaw Chyn, Wu, Catherine J., Allan, John N., Furman, Richard R., Goh, Boon Cher, Pervaiz, Shazib, Coppé, Jean-Philippe, Mitsiades, Constantine S., Davids, Matthew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645378/
https://www.ncbi.nlm.nih.gov/pubmed/37751299
http://dx.doi.org/10.1172/JCI170169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645378/
https://www.ncbi.nlm.nih.gov/pubmed/37751299
http://dx.doi.org/10.1172/JCI170169

Ejemplares similares